Terry Mahn Quoted in Law360's "High Court Biosimilar Drama Intact After Amgen-Apotex Denial"

Article posted on Law360, December 12, 2016

The U.S. Supreme Court’s refusal Monday to review a major biosimilar ruling involving Amgen and Apotex doesn’t necessarily mean that justices agree with the ruling, according to attorneys who predict that justices may use a separate case to tackle the same question about notice of biosimilar sales.

“Having dismissed the Amgen v. Apotex petition leaves the law as it is but doesn’t necessarily mean the court isn’t going to decide it,” Fish & Richardson P.C. principal Terry G. Mahn said. “This could be a total nonevent.”

To read the full article, click here.